Class II recall: Novartis Pharmaceuticals Corporation: Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufac
The FDA has classified as a Class II recall a batch of Novartis Pharmaceuticals' Diovan (valsartan) 160 mg tablets, 90-count bottles, NDC 0078-0359-34, manufactured by Patheon Manufacturing Services LLC and distributed by Novartis Pharmaceutical Corp. The recall was issued because the product failed dissolution specifications, according to the FDA recall notice.
Most relevant for: patients taking Diovan (valsartan) 160 mg from the recalled batch who have hypertension or heart disease requiring angiotensin II receptor blocker therapy
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More internal medicine updates
- Long-acting injectable noninferior to oral HIV therapy in adherence trialOct 15, 2026
- Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Ph-Positive ALL TrialOct 15, 2026
- Isoflurane sedation does not lower mortality in hypoxemic respiratory failureOct 14, 2026
- Trial finds higher mortality with intermittent vs continuous renal-replacement therapyOct 14, 2026
- No Overall Rise in Birth Defects With Early Benzodiazepine UseOct 13, 2026